Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Fair Value Measurements (Details Textual)

v3.7.0.1
Note 4 - Fair Value Measurements (Details Textual) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Apr. 30, 2017
Mar. 31, 2017
Mar. 31, 2017
Mar. 31, 2016
Aug. 01, 2016
Mar. 14, 2016
Nov. 03, 2014
Payment for Contingent Consideration Liability   $ 23,300          
Payment for Contingent Consideration Liability, Financing Activities   14,200 $ 14,203      
Payment for Contingent Consideration Liability, Operating Activities   9,100          
CyVek, Inc. [Member]              
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High   35,000 35,000        
Business Combination, Liabilities Arising from Contingencies, Amount Recognized             $ 35,000
Zephyrus [Member]              
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High   7,000 7,000        
Business Combination, Liabilities Arising from Contingencies, Amount Recognized           $ 6,500  
Payment for Contingent Consideration Liability   3,500          
Advanced Cell Diagnostics (ACD) [Member]              
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High   75,000 75,000   $ 75,000    
Business Combination, Liabilities Arising from Contingencies, Amount Recognized         $ 38,200    
Payment for Contingent Consideration Liability   19,800          
Advanced Cell Diagnostics (ACD) [Member] | Subsequent Event [Member]              
Payment for Contingent Consideration Liability $ 5,200            
Advance Cell Diagnostics (ACD), Zephyrus, and CyVek Inc.[Member]              
Business Combination, Liabilities Arising from Contingencies, Amount Recognized   $ 79,700 $ 79,700